Novartis’ Martin Seidel Joins IFM Therapeutics as V.P. of R&D

Martin Seidel is joining IFM Therapeutics to become the Boston biotech’s executive vice president of research and development. Seidel comes to IFM from Novartis (NYSE: [[ticker:NVS]]), where he was most recently global head of strategic alliances for the Novartis Institutes for Biomedical Research (NBIR). Before that, he was head of NBIR’s Genomics Institute of the Novartis Research Foundation. IFM is developing drugs that target the innate immune system to treat cancer, and inflammatory and autoimmune diseases.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.